JUL 22, 2022 7:10 PM PDT

Researchers Say Nasal Boosters Will be Important to Stopping COVID

WRITTEN BY: Carmen Leitch

The SARS-CoV-2 virus has continued to evolve since the start of the pandemic, and we've moved down the list of variants before arriving at Omicron. Now, subvariants of Omicron are becoming dominant the world over. Scientists have said they really can't say what might come next. It seems likely that the virus will continue to evolve, potentially in a chronically ill patient. Another subvariant of Omicron may arise, but it's also possible that a new variant entirely may emerge, or a subvariant of something we've seen before, like Delta, may appear. If we are going to get ahead of the virus, we may have to develop a nasal spray, suggested new research in Science Immunology. An accompanying commentary stresses the importance of intranasal vaccines for COVID.

Cropped from a transmission electron micrograph of SARS-CoV-2 Omicron virus particles (pink) replicating within the cytoplasm of an infected CCL-81 cell (teal). Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID

Previous work has shown that intranasal vaccines could be very effective, especially because that is how SARS-CoV-2 enters the body - through cells in the nasal and respiratory passages - the mucosal lining. Now, researchers have confirmed that by demonstrating that in the airways, the immune responses of people who have been vaccinated don't perform well compared to people who have been naturally infected with the virus. In the very place where the immune system should be ready to fight the virus, mRNA vaccines don't seem to be generating a robust response.

While mRNA vaccines are able to cause a general immune response, and have been effective at preventing serious illness in most people, there have been many breakthrough infections. This study helped explain why. It seems as though the immune response from mRNA vaccines stays mostly in the blood. So while antibodies are found in circulation that can fight the virus, cells that sit in the mucosal linings, where the virus is trying to cause an infection, only have a small or moderate neutralizing response.

Only unvaccinated people that had been very sick with COVID-19 attacked the virus in both the airways and the bloodstream, which the researchers noted is far from ideal.

"The Omicron variant almost completely escaped neutralization by mucosal antibodies in individuals who received mRNA vaccines and in previously infected individuals," said Jie Sun, a Professor of Medicine, among other appointments, at UVA. "Our data showed that mRNA vaccination also did not induce sufficient tissue-residing cellular immunity in the airways, another arm of our immune system to prevent the entry of the virus into our bodies."

The scientists also found a way forward, however. In a mouse model that was given an intranasal vaccine in combination with an mRNA vaccine, the immune response was vigorous in the bloodstream and in the lungs. These mice were able to attack both the original strain of SARS-CoV-2 as well as the Omicron variant, Sun said.

"Our data suggest that an intranasal vaccine-boosting strategy will be critical to protect people against emerging variants of concern," Sun noted. "The nasal vaccine provides a mucosal antigen boost to the pre-existing memory of T and B cells that direct immune response, resulting in higher cellular and humoral immunity."

Although there are intranasal vaccines in development for SARS-CoV-2/COVID-19, none have been approved for use in the US yet. Some that have already been made have shown the potential for side effects. An intranasal vaccine has been tested and approved in China, but the mucosal immunity it generates has not been evaluated yet, said Sun.

Sun's team was the first to demonstrate that the immune response to COVID-19 causes permanent lung damage in unvaccinated, hospitalized patients. They are planning to continue to study the virus and look for ways to stop it.

Sources: University of Virginia, Science Immunology

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JAN 18, 2022
Immunology
Omicron Can't Dodge T Cells
JAN 18, 2022
Omicron Can't Dodge T Cells
The Omicron variant was first reported in November 2021. More recently, a surge of infections worldwide has led to wides ...
JAN 20, 2022
Cardiology
New Imaging Study Shows How COVID Damages the Heart
JAN 20, 2022
New Imaging Study Shows How COVID Damages the Heart
New research has shown changes to heart muscle tissue in patients who died of COVID-19.
JAN 31, 2022
Health & Medicine
Genetic Risk Factor Identified for COVID-19 Loss of Smell
JAN 31, 2022
Genetic Risk Factor Identified for COVID-19 Loss of Smell
Scientists have identified a common genetic risk factor for the loss of smell due to COVID-19. Six months after testing ...
FEB 26, 2022
Health & Medicine
Vitamin D Deficiency Linked to Increased Risk of COVID Infection and More Severe Symptoms
FEB 26, 2022
Vitamin D Deficiency Linked to Increased Risk of COVID Infection and More Severe Symptoms
A century ago before effective antibiotics were available, tuberculosis patients were placed outside on sunny days becau ...
MAR 10, 2022
Cardiology
Blood Pressure Rose Due to the COVID-19 Pandemic
MAR 10, 2022
Blood Pressure Rose Due to the COVID-19 Pandemic
COVID-19 disrupted the lives of millions of people, and two new studies have shown that it also increased blood pressure ...
AUG 09, 2022
Microbiology
An Inhaled COVID-19 Treatment Halts Viral Replication
AUG 09, 2022
An Inhaled COVID-19 Treatment Halts Viral Replication
This new approach could also be effective against many different types of RNA viruses.
Loading Comments...